0.0288USD+62.71%Mkt Cap: —P/E: 0.102d ago
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United …
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit-48.27M $
Net Income (TTM)13.27M $
Revenue/Share—
Last Price0.0288 USD
Fiscal Year End—
MR Quarter—
Employees86
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.10
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.01
EPS (TTM)0.29
EPS (Forward)—
52W Range
0.001014% of range0.1950
52W High0.1950 USD
52W Low0.0010 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE8.76%
ROA7.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-44.78M $
CapEx (TTM)933.16K $
FCF Margin—
FCF Yield—
Net Debt-97.50M $
Net Debt/EBITDA1.42
Balance Sheet
Debt/Equity0.04
Current Ratio9.22
Quick Ratio8.93
Book Value/Sh2.572 USD
Cash/Share1.128 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float62.04M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta0.53
S&P 52W Chg18.16%
Avg Vol (30d)60.81K
Avg Vol (10d)—
Technical Indicators
RSI (14)52.5
MACD-0.0045
MACD Signal-0.0043
MACD Hist.-0.0001
BB Upper0.0486 USD
BB Middle0.0269 USD
BB Lower0.0051 USD
BB Width161.78%
ATR (14)0.0184 USD
Vol Ratio (20d)47.22x